Imatinib

• A Phase 1/2 Open Label Cohort Comparative Study Evaluating the Efficacy and the safety of Gene Therapy of the Sickle Cell Disease by Transpl… Recruiting
  2025-521257-17-00 Phase I (FiH) 1 country Assistance Publique Hopitaux De Paris
• Precision cancer medicine in hard-to-treat rare cancers - repurposing drugs in earlier lines of treatment - MATRIX-RARE. Recruiting
  2024-513779-42-02 Phase II 1 country Oslo University Hospital HF
• EWALL-PH-03: An open label, 2-arm, Randomised phase II study to Compare the Safety and Efficacy of Ponatinib plus Chemotherapy with Imatinib… Recruiting
  2023-505330-95-01 Phase II 3 countries Cardiff University
• A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting
  2024-517966-40-00 Phase II 1 country Goethe University Frankfurt
• Asciminib Roll-over Study Recruiting
  2023-507557-16-00 Phase III 14 countries Novartis Pharma AG
• Use of Imatinib to convert triple negative breast cancer into ER-positive breast cancer - I-CONIC Recruiting
  2024-511141-19-00 Phase II 1 country Vaestra Goetalandsregionen
• A prospective, randomized, multicenter, comparative study of the efficacy of imatinib resumption combined with atezolizumab versus imatinib … Recruiting
  2022-503068-34-00 Phase II 1 country Centre Leon Berard
• Improving public cancer care by implementing precision medicine in Norway Recruiting
  2023-507894-16-00 Phase II 1 country Oslo University Hospital HF
• A Treatment Study Protocol for Participants 0-45 Years With Acute Lymphoblastic Leukaemia Recruiting
  2022-501050-11-01 Phase II/III 14 countries Karolinska University Hospital
• AITIK-Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and Impact on the Immune System Ended
  2024-515479-36-00 Phase III 1 country Centre Hospitalier Universitaire De Poitiers
• A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP Ended
  2023-508838-33-00 Phase III 15 countries Novartis Pharma AG
• The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and… Ended
  2023-508968-30-00 Phase III 1 country Fondazione Gimema Franco Mandelli Onlus
• A Prospective Phase II Clinical Trial Evaluating the Efficacy and the Safety of Tyrosine Kinase Inhibitors Withdrawal After a Previous Two-s… Ended
  2024-514592-17-00 Phase II 1 country Masarykova Univerzita
• An Efficacy Study Comparing Ponatinib Versus Imatinib, Administered in Combination with Reduced-Intensity Chemotherapy, in Participants with… Ended
  2023-508463-71-00 Phase III 6 countries Takeda Development Center Americas Inc.
• International trial in Philadelphia chromosome-positive acute lymphoblastic leukemia Ended
  2024-515499-12-00 Phase III 12 countries Universita Degli Studi Di Milano Bicocca
• Sustained treatment-free period in the course of a disease when symptoms become less severe in BCR-ABL+ chronic myeloid leukemia: a prospect… Ended
  2023-510434-83-00 Phase IV 2 countries Fondazione Gimema Franco Mandelli Onlus
• Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia (REMAP-CAP) Ended
  2023-507889-89-00 Phase III 13 countries Universitair Medisch Centrum Utrecht
• Further 2 years of adjuvant imatinib may improve recurrence-free survival (RFS) of patients who are at a high risk of GIST recurrence despit… Ended
  2024-512243-23-00 Phase III 8 countries Region Skane
• A phase 3, randomised, double-blind, placebo-controlled, parallel-arm efficacy trial of Imatinib in acute ischaemic stroke Halted
  2023-506178-11-00 Phase III 1 country Karolinska Institutet
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial – Follow Up Long Term Extension (IMPAHCT-FUL) Ended
  2023-508735-31-00 Phase III 14 countries Aerovate Therapeutics Inc.
• Inhaled Imatinib Pulmonary Arterial Hypertension Clinical Trial (IMPAHCT) or A Phase 2b/3, Randomized, Controlled, 24-week Dose Ranging and … Ended
  2023-508734-34-00 Phase II/III 14 countries Aerovate Therapeutics Inc.
• A clinical trial on an individualized treatment strategy for patients with metastatic non-clear cell kidney cancer Ended
  2024-519070-39-00 Phase II 1 country Region Hovedstaden
• Study of efficacy and safety of asciminib in addition to imatinib in CML-CP patients without a deep level or response on imatinib Ended
  2024-515040-23-00 Phase II 5 countries Novartis Pharma AG

Showing 1–23 of 23 trials